Relapsed/Refractory Multiple Myeloma (RRMM)

Relapsed/Refractory Multiple Myeloma (RRMM) is the indication for 3 drugs in DrugBank. It is covered by 8 curated, structured indications.

Also known as: Relapsed Or Refractory Multiple Myeloma · Relapsed Refractory Multiple Myeloma · Relapsed and Refractory Multiple Myeloma · Relapsed and/or Refractory Multiple Myeloma · Relapsed/Refractory Multiple Myeloma
Classified under: Cardiovascular Diseases
Hemic and Lymphatic Diseases
Immune System Diseases
Neoplasms
Indicated drugs: Belantamab mafodotin
Carfilzomib
Melphalan flufenamide

Resolves to

Vocabularies

MedDRA10081847UMLSC4551538

What you can answer from here — as of October 22, 2026

3Indicated drugsWith each drug's targets and mechanism

Listed above

8Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

240Clinical trialsPhase, status and sponsor resolved per trial

7Drugs reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Relapsed/Refractory Multiple Myeloma (RRMM) share a target, and which companies have late-stage candidates against it?

Create a free account or log in to explore the full data card.